Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
64 hedge funds and large institutions have $34M invested in Osiris Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 8 closing their positions.
0% more call options, than puts
Call options by funds: $35K | Put options by funds: $35K
6% less funds holding
Funds holding: 68 → 64 (-4)
6% less capital invested
Capital invested by funds: $36.2M → $34M (-$2.25M)
40% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 25
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$273K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$57.4K |
| 3 |
Citigroup
New York
|
+$54.6K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$53K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$474K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$361K |
| 3 |
PCMI
Princeton Capital Management Inc
Princeton,
New Jersey
|
-$177K |
| 4 |
Renaissance Technologies
New York
|
-$164K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$117K |
OSIR Hedge Fund Activity: Q3 2016 in Review
64 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q3 2016, worth a combined $34M — down 6.2% from $36.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OSIR and 4 opened new positions — a net loss of 4 holders — while 25 trimmed existing stakes and 15 added.
The largest buyer was BlackRock Fund Advisors, adding an estimated $273K. The largest seller was Fidelity Investments, cutting an estimated $474K.
- 64 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q3 2016, down from 68 in Q2 2016.
- Funds reported $34M of Osiris Therapeutics, Inc. Common Stock stock for Q3 2016, down 6.2% quarter-over-quarter.
- 4 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q3 2016 and 8 closed out, a net change of -4 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $273K added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q3 2016 was Fidelity Investments, an estimated $474K sold.
Based on aggregated 13F filings for Q3 2016.